1/10/2024 0 Comments Default password to mguardWe evaluated 1-year clinical and angiographic results. In the MGUARD for Acute ST Elevation Reperfusion trial, the primary end point of complete ST-segment resolution was significantly improved with the MGuard compared with control. The MGuard, a bare metal stent covered with a polymer mesh, was designed to reduce distal embolization during percutaneous coronary intervention in ST-segment-elevation myocardial infarction. However, comparative data from ongoing randomized clinical trials are still required to confirm the long-term efficacy of the MGuard stent implantation in patients with STEMI. The early safety and efficacy of the MGuard stent was maintained during the long-term follow-up. ![]() There was no decrease in the left ventricular ejection fraction and no enlargement of the left ventricle between index and long-term follow-up echocardiogram. ![]() The long-term cardiac mortality was 7.0%, with MACCE rate of 8.8%. The long-term follow-up of the study was successfully performed in 57 patients (mean follow-up of 38.7☓.1 months). At 6 months the overall rate of major adverse cardiac and cerebrovascular events (MACCE composite of cardiac death, nonfatal target vessel reinfarction, target lesion revascularization, and stroke) was 1.7%. : The angiographic success of PCI was achieved in 96.7% with the final TIMI grade 3 flow in 90.0% of patients. In this multicenter study a total of 60 patients with STEMI ≤12 hours treated with the MGuard stent were enrolled. To assess the long-term safety and efficacy of the MGuard stent implantation during primary PCI for STEMI. However, data on the long-term performance of the MGuard stent are limited. ![]() The MGuard stent (bare-metal stent wrapped externally with polymer mesh sleeve) was introduced to reduce the risk of distal embolization and no-reflow phenomenon during percutaneous coronary intervention (PCI) in the thrombus containing lesions, including ST-segment elevation myocardial infarction (STEMI). This article discusses the data concerning safety and efficacy of mesh covered stent implantation in a ST-segment elevation myocardial infarction setting, as well as during percutaneous coronary intervention in saphenous venous grafts. Recently, the MGuard stent (Inspire MD, Tel Aviv, Israel), a bare-metal stent covered by micron level mesh, which allows to prevent distal embolization by blocking the atherothrombi prolapse through the stent struts during deployment has been introduced. manual aspiration catheters/mechanical thrombectomy, proximal and distal protection devices) were introduced, in the last years, to reduce the risk of angiographic complications during percutaneous coronary intervention and to improve myocardial reperfusion. Several pharmacological agents, as well as mechanical devices (i.e. Effectiveness of percutaneous coronary intervention (PCI) within thrombus containing lesions (ST-segment elevation myocardial infarction setting, degenerated saphenous venous grafts) is limited by the risk of occurrence of distal embolization and no-reflow phenomenon.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |